For two years, comparing semaglutide and tirzepatide required extrapolating from separate trials conducted in different patient populations. That changed in 2025 with the publication of SURMOUNT-5 — the first randomised controlled trial to directly pit both drugs against each other in the same study.
The result confirmed what the mechanistic difference between the two drugs predicted: tirzepatide's dual GIP/GLP-1 mechanism produces meaningfully greater weight loss. But the margin, and what it means for the average patient, deserves a closer look than most coverage provides.
The SURMOUNT-5 head-to-head results
SURMOUNT-5 enrolled 751 adults with obesity but without type 2 diabetes, randomised to either tirzepatide (10 or 15mg) or semaglutide (1.7 or 2.4mg) at maximum tolerated doses for 72 weeks.
Tirzepatide: −20.2% body weight (95% CI, −21.4 to −19.1)
Semaglutide: −13.7% body weight (95% CI, −14.9 to −12.6)
Difference: approximately 6.5 percentage points in favour of tirzepatide
To put those numbers in concrete terms: for a 100kg person, tirzepatide produced approximately 20.2kg of weight loss versus 13.7kg for semaglutide over 72 weeks. Both outcomes represent clinically meaningful weight loss — a 13.7% reduction is a significant health improvement. But the gap is real and statistically robust.
The secondary endpoints reinforced the picture. Waist circumference reduction was significantly greater with tirzepatide. More tirzepatide participants achieved the ≥15%, ≥20%, and ≥25% weight loss thresholds.
Why tirzepatide produces more weight loss
Semaglutide acts on a single receptor — GLP-1 — which regulates appetite, gastric emptying, and insulin secretion. Tirzepatide adds a second target: the GIP (glucose-dependent insulinotropic polypeptide) receptor.
The GIP component was initially expected to be neutral or even counterproductive for weight loss — GIP was known to promote fat storage. What the trials revealed is that GIP receptor activation alongside GLP-1 agonism appears to produce synergistic metabolic effects, particularly in adipose tissue, that drive meaningfully greater weight reduction.
The GIP receptor is expressed directly on fat cells, and co-activation with GLP-1 receptors appears to improve fat mobilisation and energy expenditure in ways that single GLP-1 agonism alone doesn't achieve.
Side effects — is tirzepatide better tolerated?
Despite producing greater weight loss, tirzepatide in SURMOUNT-5 showed comparable or slightly lower rates of GI side effects versus semaglutide at equivalent efficacy doses. This counterintuitive finding may relate to tirzepatide's somewhat less pronounced gastric emptying delay compared to semaglutide.
| Side effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | ~44% (any grade) | ~39% (any grade) |
| Vomiting | ~24% | ~22% |
| Diarrhoea | ~29% | ~26% |
| Constipation | ~24% | ~27% |
| Discontinuation due to AEs | ~8% | ~6% |
Both drugs require dose escalation to minimise GI side effects. The mandatory 4-week escalation schedule is critical — patients who rush to therapeutic doses experience significantly higher discontinuation rates.
Cardiovascular outcomes — semaglutide's established advantage
Semaglutide has a crucial advantage in one domain: cardiovascular outcomes data. The SELECT trial (2023) enrolled 17,604 overweight or obese adults without diabetes and demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide. This is the strongest cardiovascular outcomes evidence for any GLP-1 class drug.
Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. The mechanistic case for cardiovascular benefit is strong, and early data is encouraging, but semaglutide's SELECT data is mature and established. For patients where cardiovascular risk reduction is the primary goal, semaglutide's evidence base is currently more complete.
Cost and access in 2026
The cost picture has evolved significantly. Compounded semaglutide availability fluctuated following FDA shortage determinations — the shortage exception that previously enabled widespread compounding ended in early 2025 for tirzepatide, and access has tightened. Both branded products remain expensive without insurance coverage.
| Factor | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Brand-name list price | ~$1,350/month | ~$1,086/month |
| LillyDirect self-pay vials | N/A | $299–$499/month |
| Oral option | Yes (Rybelsus — daily pill) | Expected late 2026 |
| Compounded availability | Tightened in 2025 | Restricted since early 2025 |
| Insurance coverage | Growing — varies by plan | Growing — varies by plan |
| Cardiovascular outcomes trial | Complete — SELECT 2023 | Ongoing |
| Head-to-head weight loss | Superior — SURMOUNT-5 |
Which should you choose?
If weight loss magnitude is the primary goal and cost/access is not a barrier: the evidence favours tirzepatide. The SURMOUNT-5 data is definitive on this point.
If cardiovascular risk reduction is the primary goal: semaglutide's SELECT trial data is more established. Tirzepatide will likely produce comparable cardiovascular benefits but the large-scale trial data isn't yet complete.
If you're already on semaglutide with good results and tolerability: there's no strong reason to switch. A 13.7% weight loss is clinically meaningful. The incremental benefit of tirzepatide (~6.5 percentage points more) may or may not be worth the transition for someone already responding well.
If cost is the primary constraint: the LillyDirect self-pay vial programme makes tirzepatide unexpectedly accessible at $299–$499/month — currently the most affordable regulated route to a GLP-1 drug for cash-pay patients.
Both drugs require ongoing use to maintain results. The SURMOUNT-4 trial confirmed significant weight regain occurs when treatment is stopped. These are long-term medications, not short courses. Discuss duration and monitoring with a healthcare provider before starting either drug.
Muscle loss — the underappreciated challenge
Both drugs produce weight loss that includes lean mass alongside fat mass. Without active intervention, DEXA data from clinical users shows lean mass losses of 25–40% of total weight lost. For most users this represents 3–5kg of muscle over a typical treatment course.
The practical implication: protein intake of at least 1.6g/kg of body weight per day and resistance training at least 3 times per week are not optional add-ons — they are the difference between improved body composition and becoming a lighter but weaker version of your starting point. Some practitioners also stack GH-axis peptides to support lean mass preservation.